BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu X, Xia F, Lee J, Li F, Lu X, Zhuo X, Nie G, Ling D. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Adv Sci (Weinh) 2021;8:2002545. [PMID: 33854877 DOI: 10.1002/advs.202002545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Alshememry AK, Alsaleh NB, Alkhudair N, Alzhrani R, Alshamsan A. Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: Pre-clinical and clinical overview. Front Pharmacol 2022;13:933457. [DOI: 10.3389/fphar.2022.933457] [Reference Citation Analysis]
2 Tang X, Du X, Yu Y, Qin M, Qian L, Zhang M, Yang Y, Yu Q, Gan Z. Deep-Penetrating Triple-Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. Small 2022;:e2202834. [PMID: 35808966 DOI: 10.1002/smll.202202834] [Reference Citation Analysis]
3 Tarannum M, Vivero-Escoto JL. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment. Adv Drug Deliv Rev 2022;187:114357. [PMID: 35605679 DOI: 10.1016/j.addr.2022.114357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Won EJ, Park H, Yoon TJ, Cho YS. Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics. Pharmaceutics 2022;14:137. [PMID: 35057033 DOI: 10.3390/pharmaceutics14010137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Feng Z, Meng H. Efficient nano-enabled therapy for gastrointestinal cancer using silicasome delivery technology. Sci China Chem 2021;64:1946-57. [DOI: 10.1007/s11426-021-1126-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
6 Balachandran YL, Li X, Jiang X. Biodegradable freestanding rare-earth nanosheets promote multimodal imaging and delivers CRISPR-Cas9 plasmid against tumor. Chem Commun (Camb) 2021;57:9386-9. [PMID: 34528946 DOI: 10.1039/d1cc03228c] [Reference Citation Analysis]
7 Hu X, Li F, Xia F, Wang Q, Lin P, Wei M, Gong L, Low LE, Lee JY, Ling D. Dynamic nanoassembly-based drug delivery system (DNDDS): Learning from nature. Adv Drug Deliv Rev 2021;175:113830. [PMID: 34139254 DOI: 10.1016/j.addr.2021.113830] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Guo Y, Liu Y, Wu W, Ling D, Zhang Q, Zhao P, Hu X. Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy. Biomaterials 2021;276:121018. [PMID: 34284200 DOI: 10.1016/j.biomaterials.2021.121018] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
9 Cai H, Chen Y, Xu L, Zou Y, Zhou X, Liang G, Wang D, Tao Z. Differently PEGylated Polymer Nanoparticles for Pancreatic Cancer Delivery: Using a Novel Near-Infrared Emissive and Biodegradable Polymer as the Fluorescence Tracer. Front Bioeng Biotechnol 2021;9:699610. [PMID: 34268300 DOI: 10.3389/fbioe.2021.699610] [Cited by in F6Publishing: 2] [Reference Citation Analysis]